{"id":50312,"date":"2022-11-01T11:03:13","date_gmt":"2022-11-01T10:03:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/acclaimed-life-sciences-leaders-launch-impact-investment-firm-to-accelerate-health-equity\/"},"modified":"2022-11-01T11:03:13","modified_gmt":"2022-11-01T10:03:13","slug":"acclaimed-life-sciences-leaders-launch-impact-investment-firm-to-accelerate-health-equity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/acclaimed-life-sciences-leaders-launch-impact-investment-firm-to-accelerate-health-equity\/","title":{"rendered":"Acclaimed Life Sciences Leaders Launch Impact Investment Firm to Accelerate Health Equity"},"content":{"rendered":"
\n

\nImpact investment firm focuses on investing in therapies for diseases that disproportionately affect underserved populations, including ethnic minorities and the LGBTQ+ community<\/i><\/b>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Syridex Bio (“Syridex” or “the Firm”), an impact-driven, life sciences-focused firm investing in therapies that address the needs of underserved communities, has officially launched. The firm\u2019s founding, by a team of established experts with decades of experience at the nexus of life sciences, entrepreneurship, and investing, reflects the urgent need for investment intentionally directed toward addressing health inequities and the largely untapped potential for robust financial returns in this often-overlooked space.\n<\/p>\n

<\/a><\/p>\n

\nLaunching in the context of the global coronavirus pandemic and the vast healthcare inequities it revealed, Syridex Bio\u2019s investment focus is on funding therapies for diseases that disproportionately affect underserved populations, including ethnic minorities, the LGBTQ+ community, and rural dwellers. The firm\u2019s investment targets include in-development drugs and medical therapies that tackle the world\u2019s greatest health outcome disparities. By leveraging venture creation and private equity strategies, Syridex aims to finance the development of medical solutions that improve health outcomes and reduce disparities in underserved communities and thereby advance health equity in both absolute and relative terms.\n<\/p>\n

\nSquire Servance, Founder and Managing Partner, has spent more than a decade working in the biotechnology, pharmaceutical, and life sciences industries. Prior to founding Syridex, he served as Senior Vice President, General Counsel & Corporate Secretary at Repligen Corporation, a bioprocessing-focused life sciences company, where he led the legal, corporate secretary, compliance, and enterprise risk functions. He also counseled the company\u2019s Board of Directors and senior management. Servance joined Repligen from Baxter International, Inc. where he led the global legal team supporting its multi-billion-dollar global pharmaceuticals business.\n<\/p>\n

\n\u201cSyridex Bio is founded on the fundamental belief that everyone deserves the opportunity to live a healthy life,\u201d said Servance. \u201cAccelerating progress toward health equity requires unified action by a range of leaders and stakeholders, and it is increasingly clear that the investor community must play a central role. Driven by our focus on positive impact, we leverage a market-based approach to invest in therapies that intentionally serve the underserved \u2013 thus, laying the foundation for true equality in healthcare and opening the door to a brighter, healthier global future.\u201d\n<\/p>\n

\nThe minority-led firm, guided by a world-class advisory board, draws on deep relationships across the global pharmaceutical and biotechnology industries to source investment opportunities in innovative, best-in-class clinical stage or near-clinical stage therapies.\n<\/p>\n

\nThe advisory board is led by:\n<\/p>\n